Xenetic Biosciences is trading 6.47% up now at $3.29 as investors continue reacting to its August 7, 2026, second-quarter results and formal strategic review.
- The review includes potential asset sales or a reverse merger; royalty revenue increased 12% year over year, and management highlighted ongoing DNase clinical milestones.
- The company reported a $929,695 quarterly loss and $660,601 revenue, with higher legal costs tied to the review.
- No separate August 11, 2026, announcement was identified.